Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

U094 - Principles of CTCL Management: What's the Evidence?

Monday, February 19; 4:30 PM - 5:30 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Identify challenges in patient management in cutaneous T-cell lymphoma (CTCL)
  • Review evidence-based data and consensus guidelines to guide management decisions

Description

This interactive session will focus on 3 common challenging management issues that arise in caring for CTCL patients. We will review published evidence-based data and consensus guidelines using a multidisciplinary approach: 1) Staging work up for early patch/plaque CTCL - how far should we go? 2) Active surveillance in early CTCL - who, when, why? 3) Maintenance therapy in MF/CTCL - what is the evidence?

Disclosures

  • Kim, Ellen J., MD: Actelion – I(Grants/Research Funding); Galderma USA – C(H), I(Grants/Research Funding); Kyowa Hakko Kirin Pharma, Inc. – I(Grants/Research Funding); Medimmune – I(Grants/Research Funding); Medscape – SP(H); Seattle Genetics – A(H); Solgenix LLC – I(Grants/Research Funding);
  • Samimi, Sara, MD: no financial relationships exist with commercial interests.
  • Villasenor-Park, Jennifer, MD, PhD: no financial relationships exist with commercial interests.
Schedule
Monday, February 19
4:30 PM
Dr. Samimi / Staging for early CTCL
4:50 PM
Dr. Kim / Active surveillance in early CTCL
5:10 PM
Dr. Villasenor-Park / Maintenance therapy in CTCL
Event Details
  • Date
    Monday, February 19
  • Time
    4:30 PM - 5:30 PM
  • Location
    Room 5A
  • CME Credits
    1.00
  • Type
    New
Directors/Co-Directors
  • Ellen J. Kim, MD, FAAD
Speakers
  • Jennifer Villasenor-Park, MD, PhD, FAAD
  • Sara Samimi, MD, FAAD